Health Catalyst (NASDAQ:HCAT) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Health Catalyst (NASDAQ:HCAT – Get Rating) released its quarterly earnings results on Tuesday. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.05, MarketWatch Earnings reports. Health Catalyst had a negative net margin of 63.33% and a negative return on equity of 21.30%. The business had revenue of $68.09 million for the quarter, compared to the consensus estimate of $66.01 million. During the same period in the prior year, the company posted ($0.37) earnings per share. Health Catalyst’s revenue was up 21.9% compared to the same quarter last year. Health Catalyst updated its FY 2022 guidance to EPS and its Q2 2022 guidance to EPS.

Shares of HCAT traded up $0.52 during midday trading on Wednesday, hitting $13.47. 20,504 shares of the company traded hands, compared to its average volume of 719,215. The stock has a 50-day moving average of $22.49 and a 200-day moving average of $32.50. Health Catalyst has a one year low of $12.53 and a one year high of $59.50. The firm has a market cap of $726.53 million, a P/E ratio of -4.19 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.46 and a quick ratio of 5.46.

HCAT has been the topic of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of Health Catalyst in a research note on Friday, February 11th. They issued a “buy” rating and a $48.00 price target on the stock. BTIG Research dropped their price target on shares of Health Catalyst from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 25th. Zacks Investment Research lowered shares of Health Catalyst from a “buy” rating to a “hold” rating in a research note on Wednesday. SVB Leerink decreased their price target on shares of Health Catalyst from $64.00 to $48.00 and set an “outperform” rating for the company in a research note on Wednesday, March 2nd. Finally, Raymond James cut their price target on shares of Health Catalyst from $70.00 to $40.00 and set a “strong-buy” rating on the stock in a report on Friday, March 4th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $34.85.

In other news, General Counsel Daniel H. Orenstein sold 4,112 shares of the stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $26.82, for a total transaction of $110,283.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Linda Llewelyn sold 2,039 shares of the firm’s stock in a transaction on Tuesday, March 15th. The stock was sold at an average price of $21.08, for a total value of $42,982.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,286 shares of company stock worth $934,979. Company insiders own 2.00% of the company’s stock.

Several large investors have recently modified their holdings of the company. Advisor Group Holdings Inc. increased its holdings in shares of Health Catalyst by 86.3% during the first quarter. Advisor Group Holdings Inc. now owns 5,324 shares of the company’s stock valued at $137,000 after acquiring an additional 2,467 shares in the last quarter. Norges Bank bought a new position in shares of Health Catalyst in the 4th quarter worth approximately $6,029,000. BlackRock Inc. lifted its stake in shares of Health Catalyst by 0.5% in the 4th quarter. BlackRock Inc. now owns 4,699,392 shares of the company’s stock worth $186,189,000 after purchasing an additional 23,211 shares during the period. William Blair Investment Management LLC lifted its stake in shares of Health Catalyst by 1.1% in the 4th quarter. William Blair Investment Management LLC now owns 802,270 shares of the company’s stock worth $31,786,000 after purchasing an additional 8,571 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of Health Catalyst by 12.3% in the 4th quarter. California State Teachers Retirement System now owns 65,103 shares of the company’s stock worth $2,579,000 after purchasing an additional 7,115 shares during the period. Hedge funds and other institutional investors own 97.53% of the company’s stock.

Health Catalyst Company Profile (Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

Featured Articles